TempraMed Technologies Ltd.

Highlights -          TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading-          Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications-          LOI includes minimum annual purchase commitments in Year 1-          Expands TempraMed’s footprint across the Middle East and supports broader regional...

Integration into McKesson’s Medical-Surgical Solutions marketplace serving a nationwide customer base Toronto, ON – June 30, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a leader in temperature-controlled medication solutions, is pleased to announce the expansion of its relationship with McKesson Medical-Surgical (“MMS”). The agreement, dated...

Another major milestone in its continuous global IP strategy, advancing protection of VIVI Cap Smart across international markets Highlights -          Granted Patent covers the design of VIVI Cap Smart across major international, growing market-          Strengthens the Company’s intellectual property position in one of the world’s largest healthcare and consumer markets-          Supports commercialization...

Super-Pharm operates nationwide, serving millions of consumers annually Vancouver, BC - February 10, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce the rollout of its products across Super‑Pharm, Israel’s largest and...

Key Commercialization Milestone in Retail Pharmacy Network that Serves Over 2.8 Million Insured Members Vancouver, BC – February 6, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is excited to announce that it has completed...

Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed’s full product portfolio  Vancouver, BC – February 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator...

Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional channels Highlights -          Uses same fully patented, thermal-protection technology across product portfolio with four products in market that keep room temperature medications at optimal temperature-          Designed for medications...

Validation is expected to accelerate TempraMed’s path to payor reimbursement for product portfolio Highlights -          ROI model validated for savings and metrics by Validation Institute, a leading authority in healthcare value and economic credibility-          Confirms that payors covering VIVI Cap™ can achieve meaningful cost savings and return on investment-          Supports TempraMed’s planned...

Vancouver, BC – January 12, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce the fully subscribed closing of its previously announced non-brokered private placement (the "Offering"), issuing 3,322,153 units (each,...

Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activities Vancouver, BC - January 7, 2026 - TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce its first commercial...

Vancouver, BC – January 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to provide a positive recap on the year as well as a strategic outlook for the year ahead...

Expansion builds on newly granted South Korean patent, rising local demand and following the launch of digitally connected “VIVI Cap Smart” device Vancouver, BC – December 31, 2025 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive medications are stored and managed,...